Chakrabarti, SPradhan, PRoy, AHira, MBandyopadhyay, GBhattacharya, D K2006-01-302009-06-012006-01-302009-06-012006-01-30Chakrabarti S, Pradhan P, Roy A, Hira M, Bandyopadhyay G, Bhattacharya DK. Prevalence of anti HCV, HBsAg and HIV antibodies in high risk recipients of blood and blood products. Indian Journal of Public Health. 2006 Jan-Mar; 50(1): 43-4http://imsear.searo.who.int/handle/123456789/109820Along with hepatitis B virus (HBV) and human immunodeficiency virus (HIV), Hepatitis C virus (HCV) is emerging as a major transfusion hazard. 22 cases of haemophilia (A 19, B 3) and 20 cases of thalassaemia (2 16, E(2) 4) constituted the study group. Patients tested for anti HCV (using third generation ELISA), HBsAg and antibodies to HIV I and II. Prevalence of anti HCV was 54.5% in haemophilics and 5% in thalassaemics. HBsAg was detected in 9.09% haemophilics and 5% thalassaemics. No anti HIV was detected in this cohort. Anti HCV seropositivity in haemophilics has increased compare to previous studies.engAdolescentAdultAntibodies, Viral --bloodBlood Transfusion --adverse effectsChildChild, PreschoolHIV --immunologyHemophilia A --therapyHepacivirus --immunologyHepatitis B Surface Antigens --bloodHepatitis C --transmissionHumansPrevalenceSeroepidemiologic StudiesThalassemia --therapyJournal Article